Conrad Wang
Director at Eyconis · Board director at Alpheus Medical · Board director at Access Closure · Former Partner at HealthQuest Capital
New York, New York
Writes $1M – $75M checks · typically $4M
Find your path to Conrad
197 people in our graph can introduce you to Conrad.
Each arrow is one introduction. Sign up to fill in the first one.
Ask Louis Berneman to introduce you to Conrad
You →Louis · together at HEALTHCARE ROYALTY PARTNERS (2015–2019) →Conrad
Ask Jamie Chen to introduce you to Conrad
You →Jamie · 2 people · together at HEALTHCARE ROYALTY PARTNERS →Conrad
Ask Sam Okafor to introduce you to Conrad
You →Sam · together at Alpheus Medical →Conrad
Sign up to find every way you can get introduced to Conrad
- Your email: the people you already email who know Conrad
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Conrad
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
About
Conrad Wang is a Partner and Head of Drug Royalty Finance at SLR Capital Partners, focusing on healthcare and life sciences financing. His experience spans structured credit, private equity, venture capital, and growth equity investments across biotechnology, biopharmaceuticals, and medical devices. Wang has worked on transactions involving FDA regulatory pathways and serves in business development and M&A capacities within the healthcare sector.
Director at Eyconis
Intro paths
In turn, Conrad can intro founders to Eyconis's investors below.
Board director at Alpheus Medical
Intro paths
In turn, Conrad can intro founders to Alpheus Medical's investors below.
Board director at Access Closure
Co-founders at Access Closure
Experience
- SLR Capital PartnersPartner, Head of Drug Royalty Financecurrent2026 — presentNew York, New York, United States
- Alpheus Medical, IncBoard Member2025 — 2026
- Cellipont BioservicesBoard Member2024 — 2026
- Care ConnectorsBoard Member2024 — 2026
- HealthQuest CapitalPartner2023 — 2026United States
- Eyconis, IncBoard Member2023 — 2025
- OrbiMedPrincipal2019 — 2022Greater New York City Area
- AcufocusBoard Member2016 — 2019
- HealthCare Royalty PartnersPrincipal2015 — 2019
- TearscienceBoard Member2016 — 2017
- MedtronicSenior Director Corporate Development2013 — 2015Minneapolis
- Three Arch PartnersPrincipal2004 — 2013
- AccessClosureBoard member2010 — 2013Mountain View, CA
- Habit ManagementBoard member2010 — 2013
- Harvard Combined Orthopedic Residency ProgramOrthopedic Surgery Resident1999 — 2003
Skills & more
+12 more
Start-upsSurgeryClinical TrialsDue DiligenceClinical DevelopmentStrategyHospitalsFDAISO 13485Clinical ResearchClinicalBiomedical EngineeringLanguages Chinese (Mandarin)
From Conrad's professional profile.
Frequently asked questions
- Who is Conrad Wang?
- Conrad Wang is a Partner and Head of Drug Royalty Finance at SLR Capital Partners, focusing on healthcare and life sciences financing. His experience spans structured credit, private equity, venture capital, and growth equity investments across biotechnology, biopharmaceuticals, and medical devices. Wang has worked on transactions involving FDA regulatory pathways and serves in business development and M&A capacities within the healthcare sector.
- Where does Conrad Wang work?
- Conrad Wang is Board director at Alpheus Medical and Board director at Access Closure.
- What check size does Conrad Wang write?
- Conrad Wang typically writes checks of $1M – $75M.
- Where did Conrad Wang go to school?
- Conrad Wang studied at Harvard Business School (MBA); Harvard Medical School (MD); Massachusetts Institute of Technology (SB, Mechanical Engineering).
Same school
Also attended Harvard Business School2,000
+ 1,994 more
Also attended Harvard Medical School336
+ 330 more
Also attended Massachusetts Institute of Technology2,000
+ 1,994 more
Shared employers
Also worked at Care Connectors2
Also worked at HealthQuest Capital8
+ 2 more
Also worked at Eyconis, Inc3
Also worked at HealthCare Royalty Partners17
+ 11 more











































